NEW YORK, June 15 /PRNewswire/ -- Dr. Lawrence D. Muschek, president of
research and development of Trega Biosciences, Inc. (Nasdaq: TRGA), will give
a 2:30 p.m. presentation today before the BIO '98 Investor and Partnering
Conference at the New York Hilton and Towers Hotel, located at 1335 Avenue of
the Americas. He will discuss Trega's strategy for becoming a fully-
integrated drug discovery company.
In May 1998 Trega announced a research, development and license agreement
with Novartis Pharma AG, which focuses on identification, development and
commercialization of orally-active small molecules for the treatment of
obesity, Type II diabetes and Syndrome X which are diseases mediated by the
melanocortin receptor pathway.
In addition, Trega's lead compound, HP 228, is in a Phase II clinical
trial to evaluate the safety and preliminary effectiveness in treating acute,
post-surgical pain in patients undergoing elective hip or knee replacement
surgery.
Trega has enhanced its combinatorial chemistry technology by changing the
format in which it synthesizes and screens its chemical libraries from pools
or mixtures of compounds to individual or single-based arrays. Integrating
the Company's expertise in combinatorial chemistry and melanocortin biology,
Trega has initiated discovery programs in the areas of inflammatory conditions
and metabolic diseases. Melanocortins are a series of five known receptors
that are believed to play an important role in pain, obesity, diabetes and
inflammation.
Trega Biosciences is a drug discovery company, utilizing combinatorial
chemistry and other technologies to pursue the discovery of novel, small-
molecule drug therapies.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether any proposed research will result
in a proposed product, whether any proposed product can be successfully
formulated, scaled-up, developed, and commercialized, whether regulatory
approvals can be obtained, the impact of competitive products and pricing,
whether any corporate collaborations or alliances will be successful, and
other risks detailed from time to time in Trega's Securities and Exchange
Commission filings. These forward-looking statements represent Trega's
judgment as of the date of this release. Actual results may differ materially
from those projected. Trega disclaims, however, any intent or obligation to
update these forward-looking statements.
SOURCE Trega Biosciences, Inc.
 back to top
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 374050
CONTACT:
Vince Reardon, Director, Corporate
Communications of Trega Biosciences, Inc., 619-410-6555
|
